BioCentury
ARTICLE | Financial News

Roche reports 3Q13 sales of new cancer drugs

October 18, 2013 12:23 AM UTC

Roche (SIX:ROG; OTCQX:RHHBY) reported 3Q13 revenues on Thursday, including sales for its two newest drugs for HER2-positive metastatic breast cancer. The pharma recorded sales of CHF78 million ($85.8 million) in worldwide 3Q13 sales of breast cancer drug Perjeta pertuzumab, which it launched in the EU in March and in the U.S. last June. FDA also expanded Perjeta's label to include neoadjuvant breast cancer in September. Sales of Kadcyla ado-trastuzumab emtansine ( T-DM1), which the pharma launched in the U.S. in February and in Switzerland in May, were CHF73 million ($80.3 million) for the quarter.

The pharma also disclosed that it discontinued development of parsatuzumab ( RG7414), a mAb against EGFL7-like-domain multiple 7 ( EGFL7), after it missed the primary endpoint of progression-free survival (PFS) in the Phase II NILE trial to treat first-line metastatic non-small cell lung cancer (NSCLC). The pharma said interim data from the Phase II CONGO trial also suggested parsatuzumab would miss the primary PFS endpoint for first-line metastatic colorectal cancer. ...